Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults

Inclusion Criteria: * Good general health * Available for the duration of the trial * Willing to use acceptable forms of contraception for the duration of the study Exclusion Criteria: * Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study * Neutropenia (abnormally low neutrophil count) * Alcohol or drug abuse within 12 months prior to study entry * Elevated levels of alanine aminotransferase (ALT) and serum creatinine * History of severe allergic reaction or anaphylaxis * Severe asthma * HIV-1 infected * Hepatitis C virus infected * Hepatitis B surface antigen positive * Known immunodeficiency syndrome * Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical or nasal corticosteroids are not excluded. * Live vaccine within 4 weeks prior to study entry * Killed vaccine within 2 weeks prior to study entry * Surgical removal of spleen * Blood products within 6 months prior to study entry * History of dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus) * Previously received a licensed or experimental yellow fever or dengue vaccine * Investigational agent within 30 days of study entry * Other condition that, in the opinion of the investi…